Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Akebia Therapeutics Inc.
Nieuws
Akebia Therapeutics Inc.
AKBA
NAS
: AKBA
| ISIN: US00972D1054
26/05/2023
1,130 USD
(-6,61%)
(-6,61%)
26/05/2023
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
25 mei 2023 ·
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia
· Persbericht
22 mei 2023 ·
Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
· Persbericht
22 mei 2023 ·
Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
· Persbericht
8 mei 2023 ·
Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
· Persbericht
1 mei 2023 ·
Akebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights
· Persbericht
25 april 2023 ·
Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
· Persbericht
14 april 2023 ·
Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split
· Persbericht
11 april 2023 ·
Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders
· Persbericht
7 april 2023 ·
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023
· Persbericht
4 april 2023 ·
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
· Persbericht
3 april 2023 ·
Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study
· Persbericht
30 maart 2023 ·
Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat
· Persbericht
24 maart 2023 ·
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting
· Persbericht
9 maart 2023 ·
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
· Persbericht
2 maart 2023 ·
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights
· Persbericht
23 februari 2023 ·
Akebia Receives Positive CHMP Opinion in Europe for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
· Persbericht
21 februari 2023 ·
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
· Persbericht
1 februari 2023 ·
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
· Persbericht
3 januari 2023 ·
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
· Persbericht
22 december 2022 ·
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe